2021 Highlights and What to Expect in 2022
The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond.
It addresses the impact of innovative modalities, technologies, and recent drug approvals, such as gene and cell therapy, monoclonal antibodies,
RNA-based therapeutics, and the increasing use of health data through real-world evidence and artificial intelligence. The need to gain access to early-stage drugs and novel technologies has led to a higher rate of licensing and mergers with small biopharma that are developing the same. In addition, patient engagement has been driving digital partnerships centred around digital therapeutics, decentralized clinical trials, remote monitoring, and telemedicine.
The study also provides critical insights into the key regulatory, reimbursement, and policy updates for 2021, ranging from health data standardization and quality regulation to direct drug pricing negotiations and biosimilars & generics encouragement.
Table of Contents
1. Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8
- The Impact of the Strategic Imperative 8 on the Pharmaceuticals Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Universe
- Pharmaceuticals - Factors Affecting Growth
- Growth Opportunity Analysis for the Global Pharmaceutical Industry
- 2021 Highlights and What to Expect in 2022
- Growth Drivers
- Growth Restraints
- Market Snapshot - Next-generation Biologics Modalities
- Key FDA Approvals for Novel Drugs
- Key FDA Approvals for Novel Drugs - Takeaways
- Key M&A Deals
- Key M&A Deals in the Pharma Industry - Takeaways
- Key Product Licensing Deals
- Key Product Licensing Deals - Takeaways
- Key Digital Partnership Deals
- Key Digital Partnership Deals - Key Takeaways
- Key Regulatory, Reimbursement, and Policy Updates
- Key Regulatory, Reimbursement, and Policy Updates - Takeaways
3. Growth Opportunity Universe
- Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity
- Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience
- List of Exhibits
- Legal Disclaimer
